fever pain News
-
FDA consumer health information - new steps aimed at cutting risks from acetaminophen
FDA has taken new steps to cut the risk of severe liver injury associated with use of the pain- and fever- reducing drug acetaminophen. These steps include asking makers of prescription products that contain acetaminophen to limit how much of it is placed in each tablet or capsule. Learn more about FDA's measures, and the safe use products containing acetaminophen, at ...
-
CIHs Qualified to Assist with Ebola Outbreak
This year, the largest Ebola epidemic in history occurred in multiple countries across West Africa. In September, a person who traveled from Africa to the United States was diagnosed with the condition in Texas. The virus then spread to several healthcare workers who provided the patient with medical care. Others who offered medical care in West Africa have also become infected and have been ...
-
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
Orginally published by https://www.globenewswire.com/ Emergent BioSolutions Inc. (NYSE:EBS) announced today a research award by the U.S. Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) to evaluate efficacy of the company’s single-dose chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate. Emergent will begin the planning phase, the first ...
-
New Legionnaires Case Identified in the Renfrew Area
A new case of Legionnaires' disease has been identified in the Renfrew area. This brings the total number of cases in the area to 11 since the infection was identified at the end of June. The latest sufferer is being treated in hospital and is said to be in a stable condition. All the previously reported cases have fully recovered. NHS Greater Glasgow and Clyde (GGC) said the source of the ...
-
Emergex Awarded £490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus
Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of 100% synthetic Priming T cell Adaptive Vaccines, today announces that it has been awarded a £490,525 grant by the UK government’s Department of Health and Social Care (‘DHSC’) to advance a synthetic T ...
-
Histoplasma Infection Risks for Workers and Vulnerable Populations in Puerto Rico
Histoplasmosis is the name of an infection caused by a fungus known as Histoplasma capsulatum. The fungus lives in the environment, particularly in soil or other materials that contain large amounts of bird or bat droppings. Outbreaks of histoplasmosis have been recorded in Puerto Rico, as well as in the Dominican Republic and other parts of the Caribbean. The Centers for Disease Control and ...
-
Histoplasmosis Infection Risks for Workers & Vulnerable Populations
ScienceNews published an article last year about the spread of three types of fungi that can cause serious lung diseases. One of these was Histoplasma which causes histoplasmosis, an infection once mainly found in the Midwest, but in more recent times infections have been recorded in at least 47 states. Histoplasma capsulatum lives in the environment, particularly in soil or other materials ...
-
FDA Accepts Dupixent (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) 300 mg weekly to treat adult and pediatric patients aged 12 years and older with eosinophilic esophagitis (EoE), a chronic and progressive type 2 inflammatory ...
-
Dupixent (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union. Dupixent is now also approved in children aged 6 to 11 years as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised ...
-
Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
RBX2660 pivotal Phase 3 trial successfully met the primary endpoint; data presented today at Digestive Disease Week® (DDW) RBX2660 is the first microbiota-based live biotherapeutic to demonstrate efficacy as early as first recurrence of Clostridioides difficile (C. difficile) infection RBX2660 Phase 3 data add to the world’s largest and most robust clinical program ever conducted in ...
-
Ferring to Present Award-Winning, Landmark Research for Investigational Microbiota-Based Live Biotherapeutic RBX2660 at IDWeek 2021
Analysis of data from five RBX2660 prospective studies is one of only four abstracts to receive the coveted IDWeek 2021 Program Committee Choice award for outstanding scientific research. Ferring and Rebiotix will present new data showing an association between clinical outcomes and restoration of the microbiome Research from the Phase 3 PUNCH CD3 trial on the effects of RBX2660 on deadly ...
-
UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty cancers, today announced the first published report of real-world experience utilizing the antegrade approach for Jelmyto® (mitomycin) for pyelocalyceal solution administration in the Journal of Urology online on February 7, 2022. This report provides a stepwise ...
-
INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201
INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that several volunteers have been dosed with its DNA-based, intradermal Ebola vaccine candidate, INO-4201, as part of a randomized, placebo-controlled, Phase 1b clinical trial ...
-
Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties
Data from award-winning presentation at IDWeek 2021 represents the first time Ferring is showcasing the RBX2660 clinical development program as a whole, comprising the largest, most robust program ever conducted in the field of microbiome-based therapeutics for recurrent C. difficile infection (rCDI) Only gut microbiome research program with five clinical studies demonstrating consistent ...
-
Royal Government of Bhutan, Merck and Australian Cervical Cancer Foundation partner on vaccination program with GARDASIL(R) for girls and young women of Bhutan
The Royal Government of Bhutan, Merck (which is known as MSD outside the United States and Canada) and the Australian Cervical Cancer Foundation (ACCF) today launched a national vaccination program with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls and young women in Bhutan. In an effort to reduce the burden of cervical cancer, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you